PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors

On November 20, 2026 PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, reported updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data presented include investigator-assessed efficacy across all tumor types, including the primary analysis population of 65 platinum-resistant/refractory ovarian cancer patients who received prior standard of care. In this group, the overall response rate (ORR) was 48%, with a median duration of response of 10.4 months. In the overall population across all cohorts among 168 evaluable patients, the ORR was 36% and the median duration of response was 8.1 months.

Results were presented today in a late breaking oral presentation by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.

"Patients with platinum-resistant ovarian cancer who have progressed on standard therapies have few treatment options," said Dr. Schram. "In this heavily pretreated population, nearly half of patients with platinum-resistant/refractory ovarian cancer responded to rezatapopt, and those responses lasted a median of more than 10 months. These results support rezatapopt as a potential new targeted option for patients whose tumors harbor a TP53 Y220C mutation."

"The primary analysis reinforces the consistent, durable activity of rezatapopt in patients with platinum-resistant ovarian cancer that has been observed throughout the study," said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. "For patients who have endured multiple rounds of chemotherapy, rezatapopt has the potential to be a single-agent, chemotherapy-free, once-daily oral option they can take at home. We expect to submit our NDA for accelerated approval in the first quarter of 2027."

The Phase 2 clinical trial data as of a September 4, 2026 data cutoff date are summarized below:

Patient Population

•
The safety population consisted of 180 patients across tumor types, including 113 ovarian cancer patients, treated with at least one dose of rezatapopt 2000 mg once daily as monotherapy.

•
The efficacy population consisted of 168 patients, including 101 ovarian cancer patients, treated with at least one dose of rezatapopt as of the data cutoff date and either had ≥1 post-baseline tumor assessment or discontinued early.

•
In the overall population, patients received a median of 3 prior lines of systemic therapy (range: 0-9) and median age was 65 years (range: 33-91).

•
In the ovarian cancer cohort, 93% of patients had high-grade serous ovarian cancer and 97% had platinum-resistant/refractory disease, with a median of 4 prior lines of systemic therapy (range: 1-9).

Efficacy Results

•
Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder cancers, and ampullary carcinoma.

•
In the primary analysis population of platinum-resistant/refractory ovarian cancer patients who had received prior standard of care, the investigator-assessed confirmed overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was 48% (31/65 patients, including one CR and 30 PRs), with a 10.4-month median duration of response and an 83% disease control rate.

•
A biomarker analysis revealed that, among 50 patients with available ctDNA data, 90% (45/50) achieved a ≥50% reduction in ctDNA levels of the TP53 Y220C VAF within 3-6 weeks of starting rezatapopt which supports the on-target activity of rezatapopt.

•
In the ovarian cancer population, responses were observed regardless of additional TP53 alterations or other oncogenic alterations at baseline.

•
In the overall population across all cohorts, a 36% ORR (61/168 patients, including four complete responses [CR], 53 partial responses [PR], and four unconfirmed partial responses [uPR]), with a median time to response of 1.3 months and a median duration of response of 8.1 months was observed.

•
The cohort-specific ORRs were as follows:

•
Ovarian cancer: 45% ORR (45/101 patients, including four confirmed CRs, 37 confirmed PRs, and four uPRs)

•
Lung cancer: 21% confirmed ORR (4/19 patients)

•
Breast cancer: 17% confirmed ORR (3/18 patients)

•
Endometrial cancer: 45% confirmed ORR (5/11 patients)

•
Other solid tumors: 21% confirmed ORR (4/19 patients)

Safety Results

•
Treatment-related adverse events (TRAEs) were mostly Grade 1 or 2 with the most frequent TRAEs observed (>15%) being nausea, fatigue, blood creatinine increase, vomiting, AST increase, ALT increase and anemia. The rates of individual Grade 3 TRAEs were ≤7.2%.
•
Lab abnormalities were manageable and monitorable, with most cases being transient and reversible.

•
Eleven patients (6%), including seven ovarian cancer patients, discontinued treatment due to TRAEs.

•
Rezatapopt continued to demonstrate a manageable safety profile.

About Rezatapopt

Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

About the PYNNACLE Clinical Trial

The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C advanced solid tumors, conducted across approximately 70 sites.

For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).

(Press release, PMV Pharma, NOV 20, 2026, View Source [SID1234675039])